T. Rowe Price Investment Management’s Charles River Laboratories CRL Stock Holding History

T. Rowe Price Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41	Closed	-$9K	–	711
2025 Q4	$9K	Hold	41	–	–	﹤0.01%	723
2025 Q3	$7K	Buy	+41	New	+$6.51K	﹤0.01%	741
2024 Q3	–	Sell	-112,725	Closed	-$23.3M	–	631
2024 Q2	$23.3M	Buy	112,725 +38,617	+52%	+$8.75M	0.01%	490
2024 Q1	$20.1M	Buy	+74,108	New	+$17.7M	0.01%	501

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management's CRL Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 41 shares — an estimated $9K sold.

T. Rowe Price Investment Management first reported a position in CRL in Q1 2024 and held it in 4 quarters. The position peaked at $23.3M in Q2 2024. 559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

T. Rowe Price Investment Management reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
T. Rowe Price Investment Management sold 41 Charles River Laboratories shares in Q1 2026, an estimated $9K.
T. Rowe Price Investment Management first reported a position in Charles River Laboratories in Q1 2024 and held it in 4 quarters.
T. Rowe Price Investment Management's Charles River Laboratories position peaked at $23.3M in Q2 2024.
559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.